论文部分内容阅读
目的探讨多西紫杉醇治疗老年晚期非小细胞肺癌患者的临床疗效。方法将2009年8月-2010年7月期间长沙市第一医院收治的老年晚期非小细胞肺癌患者74例随机分成2组。观察组37例,给予单药多西紫杉醇治疗,治疗方案为多西紫杉醇60 mg/m2,第1 d;对照组37例,给予多西紫杉醇联合卡铂治疗,治疗方案为多西紫杉醇60 mg/m2,第1 d;卡铂300 mg/m2,第1 d、第2 d;每3周为1个周期。结果两组患者的治疗效果、生存率差异无统计学意义(P>0.05)。观察组的不良反应发生率显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论与多西紫杉醇+卡铂联合方案相比,单用多西紫杉醇治疗老年晚期非小细胞肺癌患者的疗效、生存率相近,但是单用多西紫杉醇的并发症发生率更低,因此目前临床上可以单用多西紫杉醇治疗老年晚期非小细胞肺癌患者。
Objective To investigate the clinical efficacy of docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Seventy-four elderly patients with advanced non-small cell lung cancer admitted to the First Hospital of Changsha from August 2009 to July 2010 were randomly divided into two groups. 37 cases in the observation group were treated with docetaxel alone. The treatment regimen was docetaxel 60 mg / m2 on the first day. The control group was given 37 docetaxel combined with carboplatin. The treatment regimen was docetaxel 60 mg / m2 on day 1; carboplatin 300 mg / m2 on day 1 and day 2; every 3 weeks for 1 cycle. Results There was no significant difference in the treatment effect and survival between the two groups (P> 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group, with significant difference between the two groups (P <0.05). Conclusions Compared with docetaxel combined with docetaxel, the efficacy and efficacy of docetaxel alone in elderly patients with advanced non-small cell lung cancer are similar, but the incidence of complications with docetaxel alone is lower. Therefore, the current clinical Docetaxel can be used alone in the treatment of advanced non-small cell lung cancer in elderly patients.